These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 6803557)

  • 1. An interview with FDA commissioner Hayes.
    Small WE
    Am Pharm; 1981 Oct; NS21(10):27-36. PubMed ID: 6803557
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA regulatory compliance reconsidered.
    Tobias C
    Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969
    [No Abstract]   [Full Text] [Related]  

  • 3. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.
    Viscusi WK; Rowland SR; Dorfman HL; Walsh CJ
    Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421
    [No Abstract]   [Full Text] [Related]  

  • 4. The learned intermediary doctrine: past, present and future.
    Alsobrook HB
    Leg Med; 1994; ():269-80. PubMed ID: 7830482
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA in hot water again over cost of proposed drug labeling rule.
    Demkovich LE
    Natl J (Wash); 1979 Sep; 11(38):1568-70. PubMed ID: 10243426
    [No Abstract]   [Full Text] [Related]  

  • 6. An interview with FDA Commissioner Frank Young. Interview by Carmella Bocchino.
    Young FE
    Nurs Econ; 1989; 7(5):242-8. PubMed ID: 2812067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ephedra: yesterday, DSHEA, and tomorrow--a ten year perspective on the Dietary Supplement Health and Education Act of 1994.
    Seamon MJ; Clauson KA
    J Herb Pharmacother; 2005; 5(3):67-86. PubMed ID: 16520299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA commissioner discusses issues of concern to hospital pharmacists. Interview by William A. Zellmer.
    Goyan JE
    Am J Hosp Pharm; 1980 May; 37(5):738-40 contd. PubMed ID: 7386484
    [No Abstract]   [Full Text] [Related]  

  • 9. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 10. Dual regulatory pharmaceutical labeling schemes; the role of the Federal Preemption Doctrine.
    Fern FH; Bartell L
    Health Matrix; 1987; 5(3):17-23. PubMed ID: 10285381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current FDA directives for promoting public health.
    Hayes AH
    Am J Hosp Pharm; 1982 Mar; 39(3):427-31. PubMed ID: 7072727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDA presentation at FDA Open Conference on Sterile Drug Manufacturing. Parenteral Drug Association.
    J Pharm Sci Technol; 1994; 48(1):4-6. PubMed ID: 8004417
    [No Abstract]   [Full Text] [Related]  

  • 13. Contaminated dietary supplements.
    Carvajal R
    N Engl J Med; 2010 Jan; 362(3):274; author reply 274. PubMed ID: 20089984
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA prohibits extralabel use of two drug classes.
    J Am Vet Med Assoc; 1997 Aug; 211(3):269. PubMed ID: 9262656
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient package inserts: instruction or confusion in the marketplace?
    Young RS
    Ohio State Med J; 1981 May; 77(5):298-9. PubMed ID: 6789266
    [No Abstract]   [Full Text] [Related]  

  • 16. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compounding interest: a tragedy caused by contaminated steroids turned the spotlight on compounding pharmacies.
    Hinkley KN
    State Legis; 2013 Jun; 39(6):22-3. PubMed ID: 23805443
    [No Abstract]   [Full Text] [Related]  

  • 18. Sunscreen drug products for over-the-counter human use; final monograph. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 May; 64(98):27666-93. PubMed ID: 10558542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA law enforcement: critical to product safety.
    Rados C
    FDA Consum; 2006; 40(1):21-7. PubMed ID: 16528823
    [No Abstract]   [Full Text] [Related]  

  • 20. From off-label prescribing towards a new FDA.
    Tabarrok A
    Med Hypotheses; 2009 Jan; 72(1):11-3. PubMed ID: 18835103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.